API
< Back to all clusters
[HEALTH] · United States · 3 sources

started · updated

FDA approves pimicotinib for tenosynovial giant cell tumor

The U.S. Food and Drug Administration has approved PIMJETMI (pimicotinib), a once-daily oral colony stimulating factor-1 receptor (CSF-1R) inhibitor, for the systemic treatment of adults with symptomatic tenosynovial giant cell tumor (TGCT). The approval targets patients for whom surgical resection may cause severe morbidity or worsening functional limitations.

In the Phase 3 MANEUVER trial, pimicotinib demonstrated a 54% objective response rate compared to 3% for the placebo group at week 25. The treatment showed clinically meaningful improvements in physical function and pain management. The drug's label includes warnings regarding hepatotoxicity, embryo-fetal toxicity, and increases in serum creatinine.

TGCT is a rare, locally aggressive tumor that develops in or around joints, often leading to progressive swelling, stiffness, and reduced mobility. Pimicotinib joins other CSF-1R-directed agents, such as vimseltinib and pexidartinib, as systemic options in the United States.

Entities

Merck · PIMJETMI · U.S. Food and Drug Administration